12 investors are actively funding Oxford healthtech companies in 2026. Lightrock, L&G, and Allegis Capital co-led Ultromics' $55M Series C in July 2025. Brainomix extended its Series C to £18.8M in February 2026. UK digital health funding hit $4B in Q1 2026.
Oxford healthtech spans AI diagnostics, digital therapeutics, and medical devices. The University of Oxford's clinical research depth gives spinouts a real advantage in securing regulated evidence early.
Don't pitch without at least a regulatory pathway defined. Oxford healthtech investors expect MHRA or FDA plans before Series A. Clinical validation is non-negotiable.
Set up an Ellty data room with your preclinical data, IP documents, and regulatory strategy before outreach. Oxford healthtech VCs request materials within 48 hours of first contact.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Oxford Science Enterprises | University VC | Seed to growth | Healthtech, AI diagnostics, medtech | oxfordscienceenterprises.com |
| Lightrock | Growth equity VC | Series B to growth | Digital health, AI cardiology, diagnostics | lightrock.com |
| Legal & General | Institutional investor | Series B to growth | AI health, digital therapeutics | legalandgeneral.com |
| Allegis Capital | US healthtech VC | Series A to C | AI diagnostics, digital health | allegiscapital.com |
| Parkwalk Advisors | University spinout VC | Pre-seed to Series B | Oxford healthtech spinouts, EIS | parkwalk.vc |
| IP Group | University spinout investor | Seed to growth | Oxford healthtech, medtech | ipgroupplc.com |
| Boehringer Ingelheim Venture Fund | Corporate VC | Seed to Series B | AI imaging, therapeutics, digital health | boehringer-ingelheim.com |
| SV Health Investors | Global health VC | Series A to C | Digital health, biotech, medtech | svhealthinvestors.com |
| Longwall Ventures | Oxford early-stage VC | Seed to Series A | Oxford healthtech, medtech spinouts | longwall.vc |
| Oxford Capital | EIS/SEIS fund | Seed to Series A | Oxford-area healthtech, digital health | oxcp.com |
| GV (Google Ventures) | Corporate VC | Series A to growth | AI health, diagnostics, digital health | gv.com |
| BGF | Growth equity | £3M-£30M | Healthtech scale-ups, medtech | bgf.co.uk |
Track who opens your Oxford healthtech data room
Build an Ellty data room. See which investors open your clinical data.
Start free 14-day trialWhat is an Oxford healthtech investor?
Oxford healthtech investors back companies using technology to improve health outcomes, built on University of Oxford clinical research. They differ from generalist VCs by requiring clinical validation before leading a round.
Most Oxford healthtech deals involve co-investment. Ultromics' $55M Series C included Lightrock, L&G, Allegis Capital, OSE, and GV. Syndicated rounds are standard for clinical-stage companies.
Check sizes range from pre-seed EIS at Oxford Capital and Parkwalk to multi-million growth rounds from Lightrock and L&G. BGF covers growth-stage Oxford healthtech from £3M to £30M.
Read how Oxford biotech investors approach clinical due diligence differently. Some Oxford healthtech investors also back AI drug discovery platforms alongside diagnostics companies.
Oxford's clinical research infrastructure gives healthtech spinouts an unusually strong foundation. The combination of NHS access, Oxford University Hospitals data, and world-class engineering is what makes this ecosystem special.
12 Oxford healthtech investors
1. Oxford Science Enterprises
Oxford Science Enterprises is a £1.1B investment company and the most active Oxford healthtech investor. They co-led Kneu Health's £4.2M seed alongside Cedars-Sinai in October 2025. In 2025 they backed Ultromics ($55M Series C), Oath Surgical ($24M Series A), and Scripta Therapeutics (€10M+).
Set up an Ellty data room with your clinical data, regulatory pathway, and IP assignments before approaching OSE. Their team requests technical materials within 48 hours.
- Recent Deals: Kneu Health £4.2M seed co-lead (Oct 2025); Ultromics $55M Series C (July 2025); Oath Surgical $24M Series A (Oct 2025); 11 investments in 2025
- LinkedIn: Oxford Science Enterprises LinkedIn
- Sector Focus: Healthtech, AI diagnostics, medtech, life sciences
- Stage Focus: Seed to growth
- Location: Oxford, UK
- Website: oxfordscienceenterprises.com
2. Lightrock
Lightrock is a global growth equity investor that co-led Ultromics' $55M Series C in July 2025 alongside L&G and Allegis Capital. They focus on impact-aligned healthtech companies with scalable AI platforms. Lightrock backed Ultromics after EchoGo gained FDA clearance for heart failure detection.
- Recent Deals: Ultromics $55M Series C co-lead (July 2025); Previse Systems growth round (2025); ATEC Global $15M (2025); active January 2026 newsletter
- LinkedIn: Lightrock LinkedIn
- Sector Focus: Digital health, AI cardiology, diagnostics, impact tech
- Stage Focus: Series B to growth
- Location: London and Zurich
- Website: lightrock.com
3. Legal & General
Legal & General is a £1.1T institutional investor that co-led Ultromics' $55M Series C in July 2025. They focus on AI health platforms with US commercial traction and clinical-grade evidence. L&G invests in healthtech through its venture arm and strategic investment programme.
- Recent Deals: Ultromics $55M Series C co-lead (July 2025); Oxford Nanopore Technologies ongoing stake; UK healthtech strategic investment mandate
- LinkedIn: Legal & General LinkedIn
- Sector Focus: AI health, digital therapeutics, diagnostics
- Stage Focus: Series B to growth
- Location: London
- Website: legalandgeneral.com
4. Allegis Capital
Allegis Capital is a US-based VC that co-led Ultromics' $55M Series C in July 2025. They focus on AI diagnostics and digital health platforms with FDA clearance or a credible regulatory pathway. Allegis backs Oxford healthtech companies alongside OSE and Lightrock on US expansion rounds.
- Recent Deals: Ultromics $55M Series C co-lead (July 2025); AI diagnostics and digital health portfolio; US and UK cross-border mandate
- LinkedIn: Allegis Capital LinkedIn
- Sector Focus: AI diagnostics, digital health
- Stage Focus: Series A to C
- Location: San Francisco with UK deal flow
- Website: allegiscapital.com
5. Parkwalk Advisors
Parkwalk Advisors manages £450M+ in EIS funds and led Brainomix's £4.8M Series C extension in February 2026. They back Oxford healthtech spinouts at pre-seed and seed with EIS-eligible capital. Parkwalk co-invests with OSE on most Oxford spinout rounds.
- Recent Deals: Brainomix £4.8M Series C extension lead (Feb 2026); AccelerComm $15M (June 2025); £450M+ AUM; Oxford healthtech EIS mandate
- LinkedIn: Parkwalk Advisors LinkedIn
- Sector Focus: Oxford healthtech spinouts, EIS, medical devices
- Stage Focus: Pre-seed to Series B
- Location: London with Oxford focus
- Website: parkwalk.vc
Share your healthtech pitch with trackable links
Use Ellty to see which investors open your clinical evidence and regulatory docs.
Start free 14-day trial6. IP Group
IP Group backed Brainomix's £4.8M Series C extension via the IP Group Hostplus Innovation Fund in February 2026. They hold deep Oxford healthtech exposure and co-invest with Parkwalk and OSE. IP Group is a structural long-term investor in the Oxford healthtech ecosystem.
- Recent Deals: Brainomix £4.8M Series C extension (Feb 2026); Lumai $10M+ (April 2025); IP Group Hostplus Innovation Fund active; Oxford medtech portfolio
- LinkedIn: IP Group LinkedIn
- Sector Focus: Oxford healthtech, medtech, AI diagnostics
- Stage Focus: Seed to growth
- Location: London with Oxford focus
- Website: ipgroupplc.com
7. Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund co-led Brainomix's £14M Series C in March 2025. They focus on AI imaging, digital therapeutics, and early-stage clinical platforms. BIVF opened a new AI centre in London's King's Cross in 2026 to strengthen UK deal flow.
- Recent Deals: Brainomix £14M Series C co-lead (March 2025); London AI centre opened (2026); 5 investments in 2025-2026; AI imaging and digital health focus
- LinkedIn: Boehringer Ingelheim Venture Fund LinkedIn
- Sector Focus: AI imaging, therapeutics, digital health
- Stage Focus: Seed to Series B
- Location: London and Germany
- Website: boehringer-ingelheim.com
8. SV Health Investors
SV Health Investors is a global health VC with 50+ investment professionals in Boston and London. They backed Sitryx Therapeutics' $39M round alongside Oxford Science Enterprises. SV Health backs Oxford healthtech at Series A and B in digital therapeutics, dementia, and rare disease.
Use Ellty to share your clinical evidence with SV Health before first contact. Track which sections they review to decide how to follow up.
- Recent Deals: Sitryx Therapeutics $39M (with OSE); European healthtech Series A and B mandate; Boston and London operations; 50+ investment team
- LinkedIn: SV Health Investors LinkedIn
- Sector Focus: Digital health, biotech, dementia, rare disease
- Stage Focus: Series A to C
- Location: London and Boston
- Website: svhealthinvestors.com
9. Longwall Ventures
Longwall Ventures backs early-stage Oxford healthtech spinouts alongside OSE and Oxford Technology Management. They participated in the June 2026 Oxford Venture Tour and co-invested in Caristo's £16.3M Series A. Longwall is the most active seed co-investor in the OSE healthtech network.
- Recent Deals: Caristo £16.3M Series A (with OSE and BGF); June 2026 Oxford Venture Tour participant; Oxford healthtech seed mandate
- LinkedIn: Longwall Ventures LinkedIn
- Sector Focus: Oxford healthtech, medtech, AI diagnostics spinouts
- Stage Focus: Seed to Series A
- Location: Oxford, UK
- Website: longwall.vc
10. Oxford Capital
Oxford Capital manages EIS and SEIS funds for Oxford-area technology and life science companies. They invest in Oxford healthtech founders who need institutional capital before OSE and Parkwalk can lead. Oxford Capital co-invests with Longwall and OSE on seed rounds.
Read the due diligence documents guide before approaching Oxford Capital. EIS fund investors run document-intensive reviews even at seed stage.
- Recent Deals: NavLive £4M (May 2025); Oxford-area EIS/SEIS fund active 2025-2026; Oxford healthtech and digital health focus
- LinkedIn: Oxford Capital LinkedIn
- Sector Focus: Oxford-area healthtech, digital health, EIS
- Stage Focus: Seed to Series A
- Location: Oxford, UK
- Website: oxcp.com
11. GV (Google Ventures)
GV backed Ultromics' $55M Series C in July 2025 alongside Lightrock, L&G, and Allegis Capital. They invest in UK healthtech companies with AI-enabled clinical platforms and NHS traction. GV is one of the most active US-based investors in UK digital health companies.
- Recent Deals: Ultromics $55M Series C participant (July 2025); UK digital health and AI diagnostics portfolio; US-UK cross-border mandate
- LinkedIn: GV LinkedIn
- Sector Focus: AI health, diagnostics, digital health
- Stage Focus: Series A to growth
- Location: San Francisco with UK deal flow
- Website: gv.com
12. BGF
BGF is the most active growth equity investor in the UK and Ireland. They co-invested in Caristo's £16.3M Series A alongside OSE and Longwall Ventures. BGF backs Oxford healthtech companies past seed with £3M to £30M checks. Founders with NHS traction should approach BGF alongside SV Health at Series A.
- Recent Deals: Caristo £16.3M Series A (with OSE and Longwall); most active UK equity investor; Oxford healthtech growth mandate
- LinkedIn: BGF LinkedIn
- Sector Focus: Healthtech scale-ups, medtech, Oxford-area
- Stage Focus: Series A and beyond
- Location: UK-wide with Oxford coverage
- Website: bgf.co.uk
How Oxford healthtech VCs evaluate evidence
Clinical evidence requirements differ by stage. OSE and Longwall back Oxford healthtech at pre-seed with a concept and Oxford IP. Lightrock and L&G need FDA clearance or NHS deployment before leading.
Don't present interim data without peer-reviewed context. Oxford healthtech investors ask who reviewed your clinical methodology. Prepare those answers before any first meeting.
Most Oxford healthtech VCs run 60-90 day due diligence. IP licensing, regulatory filings, and clinical data checks all add time. Plan your runway before starting the process.
What Oxford healthtech founders get wrong
Most founders pitch the technology before the clinical problem. Oxford healthtech investors want to see the unmet need first. Start with patient outcomes, not the AI architecture.
Don't pitch without NHS traction or a letter of intent. Lightrock and L&G expect health system engagement before Series B. Even a single NHS pilot changes the conversation.
Use Ellty to organise your NHS contracts, regulatory filings, and clinical data. Track which sections investors open before following up.
Where Oxford healthtech founders meet investors
The Oxford Venture Tour in June 2026 brings together OSE, Longwall, Oxford Capital, and Oxford Technology Management. It's the best event for Oxford healthtech founders to meet seed investors in one session.
Health Innovation Oxford & Thames Valley connects Oxford spinouts to early-stage investors. OSE and Parkwalk both attend and prioritise in-person introductions.
Read the due diligence checklist for investors before managing outreach to Oxford healthtech VCs. Running 4+ investor processes in parallel requires disciplined tracking.
How to pitch an Oxford healthtech investor
Five steps that match how Oxford healthtech VCs evaluate founders before writing a check.
- 1.Define your regulatory pathway before any pitchMHRA or FDA plan is expected before OSE leads a seed.
- 2.Resolve your Oxford University IP licence upfrontOSE and Parkwalk check IP assignments in the first week.
- 3.Secure at least one NHS pilot or letter of intentLightrock and L&G need health system proof before Series B.
- 4.Approach OSE or Longwall first for pre-seed capitalBoth accept direct applications and move within 4-6 weeks.
- 5.Set up your Ellty data room before investor contactOxford healthtech VCs request clinical docs within 48 hours.
How Ellty helps you land an Oxford healthtech investor
Oxford healthtech VCs move fast once interested. Prepare your clinical materials before first contact.
- 1.Build a healthtech data room with clinical evidenceUpload trial data, regulatory docs, and financials securely.
- 2.Set link permissions before sharing with VCsRequire email to view. Protect unpublished clinical data.
- 3.Track which investors open your clinical data sectionSee who reviews your evidence slides. Follow up those VCs.
Common questions from Oxford healthtech founders
- Not at pre-seed. OSE and Longwall back founders at concept stage with strong Oxford IP.
- FDA clearance or CE marking is expected. An NHS pilot agreement also works at Series B.
- Approach OSE first. They lead most Oxford healthtech seeds and bring Parkwalk as co-lead.
- Before first contact. Oxford healthtech VCs request clinical docs within 48 hours.
- Expect 60-90 days minimum. IP licensing and regulatory reviews add significant time.
